Moreover, upon scrutinizing the TCGA database, it was discerned that individuals manifesting elevated levels of FOXK2 expression displayed enhanced responsiveness to conventional breast cancer therapeutics, including cisplatin, lapatinib, talazoparib, and tamoxifen (Figure 4e–h). Here, FOXK2 is linked to breast cancer.